Minerva Neurosciences hosted a Key Opinion Leader (KOL) event and filed an updated investor presentation regarding roluperidone, its product candidate for schizophrenia. The filing includes a revised transcript of the event to clarify that regulatory counsel's expressions of confidence regarding FDA approval were personal opinions and not assurances of future regulatory decisions.
Minerva Neurosciences reported a net income of $100.7 million for the third quarter of 2026, primarily driven by a $109.6 million non-cash gain from the change in fair value of warrant liabilities. However, the company experienced a net loss of $7.2 million for the nine months ended September 30, 2026, as research and development expenses surged to $17.6 million compared to $3.6 million in the prior year.
Minerva Neurosciences reported third quarter 2026 financial results and provided a business update on its ongoing Phase 3 trial (C19 Study) of roluperidone for negative symptoms of schizophrenia. The company expects topline efficacy data from Phase A of the trial in the second half of 2027 and remains focused on developing non-dopaminergic treatments for CNS disorders.
Term
Q3 2026
“The psychiatry field has increasingly recognized the importance of finding non-dopaminergic mechanisms in the treatment of schizophrenia, particularly for negative symptoms. Roluperidone is the only late-stage candidate targeting negative symptoms directly. The C19 study, our ongoing Phase 3 trial, is designed to confirm the effect we saw in our prior trials. We remain focused on execution and on track for topline efficacy data in the second half of 2027.”
Remy Luthringer, Ph.D., Chief Executive Officer of Minerva Neurosciences